SILO Silo Pharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1514183 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-50.0%
TTM net income YoY26.7%
TTM EPS YoY159.8%
Revenue 3-yr CAGR-20.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-12,534.1%
Net margin-10,319.0%
FCF margin—
EBITDA margin—
Returns
ROE-55.3%
ROA-49.0%
ROIC (approx.)-207.1%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets4.0%
Debt / equity0.00x
Current ratio24.43x
Interest coverage-112.82x
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $72,102 | $72,102 | $72,102 | $72,102 | $71,264 |
| Cost of revenue | $44,295 | $5,838 | $5,838 | $5,838 | $5,004 |
| Gross profit | $27,807 | $66,264 | $66,264 | $66,264 | $66,260 |
| R&D expense | $2.16M | $2.37M | $845,092 | $1.29M | $693,910 |
| SG&A expense | — | — | $390,071 | $227,259 | $162,953 |
| Operating income | -$4.28M | -$4.71M | -$3.86M | -$3.63M | -$2.74M |
| Interest expense | $37,302 | $5,084 | $4,869 | $2,199 | $3,036 |
| Pretax income | -$4.23M | -$4.39M | -$3.63M | -$3.91M | $4.18M |
| Income tax | — | — | — | — | $24,876 |
| Net income | -$4.23M | -$4.39M | -$3.70M | -$3.91M | $3.90M |
| EPS (basic) | -0.50 | -1.19 | -1.20 | — | 0.04 |
| EPS (diluted) | -0.50 | -1.19 | -1.20 | — | 0.04 |
| Weighted avg. shares (diluted) | 8.38M | 3.68M | 3.08M | 2.28M | 1.92M |
| Banking | |||||
| Net interest income | — | — | — | — | -$3,036 |
| Balance sheet | |||||
| Cash & equivalents | $4.75M | $3.91M | $3.52M | $11.37M | $9.84M |
| Short-term investments | $2.11M | $3.17M | $4.14M | — | — |
| Receivables | — | — | — | $66,010 | — |
| Inventory | — | — | — | — | $26,659 |
| Current assets | $7.39M | $7.11M | $7.68M | $11.57M | $10.40M |
| Intangibles | $217,375 | $241,215 | — | — | — |
| Total assets | $7.61M | $7.41M | $7.75M | $11.64M | $10.49M |
| Current liabilities | $650,183 | $1.66M | $775,590 | $436,318 | $490,039 |
| Total liabilities | $1.30M | $2.38M | $1.57M | $1.30M | $1.43M |
| Shareholders' equity | $6.31M | $5.03M | $6.18M | $10.34M | $9.06M |
| Shares outstanding | 887,886 | 4.48M | 2.91M | 3.16M | 1.97M |
| Cash flow statement | |||||
| Operating cash flow | -$4.66M | -$3.83M | -$3.22M | -$3.50M | -$2.28M |
| Investing cash flow | $644,021 | $973,777 | -$4.15M | $86,707 | $7.19M |
| Financing cash flow | $4.86M | $3.24M | -$471,121 | $4.94M | $3.79M |
| Stock-based compensation | $117,021 | $0 | $871,625 | $577,651 | $395,123 |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.